Obata Y, Tanaka T, Stockert E, Good R A
Proc Natl Acad Sci U S A. 1979 Oct;76(10):5289-93. doi: 10.1073/pnas.76.10.5289.
G(IX) congeneic mouse strains, C57BL/6-G(IX) (+)(B6-G(IX) (+)) and 129-G(IX) (-), have been derived from the prototype strains, B6(G(IX) (-)) and 129(G(IX) (+)). The hybrids, (B6-G(IX) (+) x 129)F(1) (G(IX) (+)F(1)) and (B6 x 129-G(IX) (-))F(1) (G(IX) (-)F(1)), differ only in regard to genetic loci controlling G(IX) antigen expression. G(IX) (+)F(1) mice spontaneously produce G(IX) antibody and often show signs of autoimmune disease and lymphoproliferative disease. G(IX) (-)F(1) mice and mice of the two parental strains (B6-G(IX) (+) and 129) of G(IX) (+)F(1) do not produce G(IX) antibody and seldom show signs of these diseases. G((ERLD)), and G((RADA1)), antibodies, natural thymocytotoxic autoantibody, and antinuclear antibodies were produced by G(IX) (+)F(1) mice. However, these four antibodies were also found in the other strains. G(IX) (+)F(1) mice develop pronounced diffuse glomerulonephritis similar to that found in systemic lupus erythematosus in man. Incidence studies in which mice were examined according to age rather than state of health showed that the lesions occurred in 38% of G(IX) (+)F(1) mice but not in G(IX) (-)F(1), B6-G(IX) (+), or 129 mice. Lymphoproliferative lesions were either reticulum cell sarcoma (RCS) type A or reactive lymphoid hyperplasia (RLH). RCS occurred more often in G(IX) (+)F(1) (38%) than in G(IX) (-)F(1) (12%) or B6-G(IX) (+) (8%). No RCS occurred in mice of the 129 strain. RLH occurred in G(IX) (+)F(1) mice (10%) but not in the other strains. From these results, the following conclusions are drawn: (i) Severe glomerulonephritis and the increased occurrence of lymphoproliferative lesions in these animals depend on the presence of G(IX) antigen; (ii) besides genes controlling G(IX) antigen expression, other genes from both parental strains are required to create the basis in the progeny F(1) mice for the development of these diseases; and (iii) the chronic production of G(IX) antibody may be necessary for the development of the severe glomerulonephritis and for the increased occurrence of lymphoproliferative diseases in G(IX) (+)F(1) mice.
G(IX) 同源小鼠品系,C57BL/6 - G(IX) (+)(B6 - G(IX) (+))和129 - G(IX) (-),源自原型品系B6(G(IX) (-))和129(G(IX) (+))。杂种小鼠,(B6 - G(IX) (+)×129)F(1)(G(IX) (+)F(1))和(B6×129 - G(IX) (-))F(1)(G(IX) (-)F(1)),仅在控制G(IX)抗原表达的基因位点上有所不同。G(IX) (+)F(1)小鼠自发产生G(IX)抗体,且常表现出自身免疫性疾病和淋巴增生性疾病的症状。G(IX) (-)F(1)小鼠以及G(IX) (+)F(1)的两个亲本品系(B6 - G(IX) (+)和129)的小鼠不产生G(IX)抗体,很少表现出这些疾病的症状。G(IX) (+)F(1)小鼠产生G((ERLD))、G((RADA1))抗体、天然胸腺细胞毒性自身抗体和抗核抗体。然而,这四种抗体在其他品系中也有发现。G(IX) (+)F(1)小鼠会发展出明显的弥漫性肾小球肾炎,类似于人类系统性红斑狼疮中所发现的情况。根据年龄而非健康状况对小鼠进行检查的发病率研究表明,38%的G(IX) (+)F(1)小鼠出现病变,而G(IX) (-)F(1)、B6 - G(IX) (+)或129小鼠则未出现。淋巴增生性病变要么是A型网状细胞肉瘤(RCS),要么是反应性淋巴样增生(RLH)。RCS在G(IX) (+)F(1)小鼠中出现的频率(38%)高于G(IX) (-)F(1)小鼠(12%)或B6 - G(IX) (+)小鼠(8%)。129品系的小鼠未出现RCS。RLH出现在G(IX) (+)F(1)小鼠中(10%),而其他品系未出现。基于这些结果,得出以下结论:(i)这些动物中严重的肾小球肾炎和淋巴增生性病变发生率的增加取决于G(IX)抗原的存在;(ii)除了控制G(IX)抗原表达的基因外,两个亲本品系的其他基因也需要在子代F(1)小鼠中为这些疾病的发展奠定基础;(iii)G(IX)抗体的持续产生可能对于G(IX) (+)F(1)小鼠中严重肾小球肾炎的发展以及淋巴增生性疾病发生率的增加是必要的。